Novo Nordisk A/S (Novo Nordisk A/S) Accounts Payable & Accrued Expense : $4,788 Mil (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Accounts Payable & Accrued Expense?

Novo Nordisk A/S's quarterly accounts payable & accrued expense increased from Jun. 2023 ($3,988 Mil) to Sep. 2023 ($4,637 Mil) and increased from Sep. 2023 ($4,637 Mil) to Dec. 2023 ($4,788 Mil).

Novo Nordisk A/S's annual accounts payable & accrued expense increased from Dec. 2021 ($1,904 Mil) to Dec. 2022 ($3,229 Mil) and increased from Dec. 2022 ($3,229 Mil) to Dec. 2023 ($4,788 Mil).

Novo Nordisk A/S Accounts Payable & Accrued Expense Historical Data

The historical data trend for Novo Nordisk A/S's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Accounts Payable & Accrued Expense Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1,572.24

1,574.71

1,903.66

3,229.15

4,787.56

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															3,229.15	2,317.54	3,987.98	4,637.15	4,787.56

Novo Nordisk A/S Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.